ストックスクリーナーアプリを入手
3.3251
1.07%
0.0351
前日終値:
$3.29
開ける：
$3.3
24時間の取引高:
30,134
Relative Volume:
0.15
時価総額：
$12.55M
収益：
-
当期純損益:
$-15.47M
株価収益率:
-3.9585
EPS:
-0.84
ネットキャッシュフロー:
$-13.51M
1週間 パフォーマンス:
-0.45%
1か月 パフォーマンス:
-30.15%
6か月 パフォーマンス:
-45.67%
1年 パフォーマンス:
-79.72%
1日の値動き範囲:
$3.1901
$3.51
1週間の範囲:
$3.00
$3.55
52週間の値動き範囲:
$3.00
$29.08
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
NLSP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| NLSP | 3.32 | 12.55M | 0 | -15.47M | -13.51M | -0.84 |
| VRTX | 449.38 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.10 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.35 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.78 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Nls Pharmaceutics Ltd (NLSP) 最新ニュース
Preclinical Program Investigates Potential of NLS’ Dual Orexin Agonists for Narcolepsy - Sleep Review
NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan
NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks
ARMISTICE CAPITAL, LLC Acquires Additional Shares in NLS Pharmac - GuruFocus.com
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com
500: Something went wrong - Investing.com India
Kadimastem Ltd. Faces Financial Uncertainty - TipRanks
NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks
What's Going On With NLS Pharmaceutics Shares Monday? - MSN
NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance
NLS Pharmaceutics and Kadimastem Announce Strategic Merger - TipRanks
NLS Pharmaceutics, Kadimastem enter definitive merger agreement - Yahoo Finance
NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - MSN
NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com Canada
Definitive Merger Agreement Reached Between NLS and Kadimastem - Sleep Review
NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - StreetInsider.com
NLSP - Insider Financial
NLS Pharmaceutics Achieves Nasdaq Compliance Milestone - TipRanks
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - AccessWire
NLSP stock touches 52-week low at $4 amid sharp annual decline - Investing.com UK
NLS Pharmaceutics Strikes Debt Forgiveness Deal - TipRanks
NLS Pharmaceutics’ $3.2 Million Common Share Offering - Global Legal Chronicle
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - AccessWire
NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges - Yahoo Finance
(NLSP) Technical Pivots with Risk Controls - Stock Traders Daily
NLS Pharmaceutics Boosts Financial Standing with Key Moves - TipRanks
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - Yahoo Finance
NLS Pharmaceutics Regains Nasdaq Compliance - TipRanks
NLS Pharmaceutics Launches New Share Purchase Warrant - TipRanks
NLS Pharmaceutics AG announced that it expects to receive $3.201614 million in funding - Marketscreener.com
NLS Pharmaceutics Shareholders Approve Agenda - TipRanks
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise - Marketscreener.com
NLS Pharmaceutics Receives Nasdaq Compliance Extension - TipRanks
NLSP stock touches 52-week high of $4.61 amid market fluctuations - Investing.com
NLS Pharmaceutics announces 1-for-40 reverse stock split - Investing.com
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - AccessWire
A year in review: NLS Pharmaceutics Ltd (NLSP)’s performance in the last year - US Post News
Market Highlights: NLS Pharmaceutics Ltd (NLSP) Ends on a Low Note at 0.14 - The Dwinnex
NLSP: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
NLS Pharmaceutics Shareholders Approve Key Measures - TipRanks
NLS Pharmaceutics Adjusts Warrants Terms - TipRanks
NLS Pharmaceutics Plans Capital Increase and Debt Restructuring - TipRanks
Investor’s Toolkit: Key Ratios for Assessing NLS Pharmaceutics Ltd (NLSP)’s Performance - The Dwinnex
Nls Pharmaceutics Ltd (NLSP) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):